جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

4 مُخرَج نتائج البحث عن «Prolactin»

مقالوصول مفتوح20252استشهاد· Semantic Scholar

Correlation between MRI findings of pituitary gland and prolactin level among hyperprolactinemia adult female Saudi patients in rural areas: A retrospective multicentric study

Medicine · مجلد 104 (2) · e40686-e40686

Identifying the prolactin threshold that necessitates pituitary magnetic resonance imaging (MRI) in patients with hyperprolactinemia remains challenging. Therefore, developing standards for serum prolactin level criteria to predict prolactinoma is critical. This study aimed to investigate the correlation between hyperprolactinemia and the presence of pituitary adenoma among Saudi female patients with verified prolactin levels. A retrospective multicentric study, including 4 regions from western Saudia Arabia between July 2020 and September 2023, included 168 female patients with abnormal prolactin levels who underwent brain MRI for the pituitary gland evaluation. The prevalence of pituitary adenoma and its associated factors and the relationship between blood prolactin levels and pituitary adenoma on brain MRI, as well as establishing the cutoff value of serum prolactin concentration linked to the existence of pituitary adenoma, were investigated and analyzed. The mean prolactin level was 72.7 ± 63.2 ng/mL. MRI findings were microadenoma in 77 (46.1%), macroadenoma in 17 (10.2%), Empty sella syndrome (ESS) in 7 (4.2%), and normal in 66 (39.5%) patients. In the ROC curve analysis, prolactin levels demonstrated a moderate degree of accuracy in predicting the existence of a pituitary adenoma (AUC = 0.640; 95% CI = 0.563-0.713; P = .0010], and the sensitivity and specificity were 40.59% and 83.33%, respectively. The ideal cutoff prolactin level for diagnosing pituitary adenoma was > 38.71 ng/mL with a sensitivity of 77.23% and specificity of 40.91%. It is prudent to perform pituitary imaging in most cases of hyperprolactinemia without event etiology, even if the condition is minor, due to the high prevalence of pituitary anomalies in female patients with hyperprolactinemia at serial sampling. A multidisciplinary strategy is necessary for a comprehensive diagnosis, treatment, and follow-up approach to improve the clinical outcomes of these individuals.

hyperprolactinemiapituitary adenomaprolactinomaserum prolactin levels
مقالوصول مفتوح20244استشهاد· Semantic Scholar

Competence of Combined Low Dose of Human Chorionic Gonadotropin (HCG) and Clomiphene Citrate (CC) Versus Continued CC during Ovulation Induction in Women with CC-Resistant Polycystic Ovarian Syndrome: A Randomized Controlled Trial

Medicina · مجلد 60 (8) · 1300-1300

Background and Objectives: Polycystic ovarian syndrome (PCOS) is a widespread endocrine disorder affecting 5–18% of females in their childbearing age. The aim of this study is to assess the efficacy of combining a low dosage of human chorionic gonadotropin (HCG) along with clomiphene citrate (CC) for stimulating ovulation in infertile women diagnosed with CC-resistant PCOS. Materials and Methods: A randomized controlled trial was carried out on 300 infertile CC-resistant PCOS women. All participants were assigned to two groups: the CC-HCG group and the CC-Placebo group. Subjects in the CC-HCG group were given CC (150 mg/day for 5 days starting on the 2nd day of the cycle) and HCG (200 IU/day SC starting on the 7th day of the cycle). Subjects in the CC-Placebo group were given CC and a placebo. The number of ovarian follicles > 18 mm, cycle cancellation rate, endometrial thickness, ovulation rate, clinical pregnancy rate, and occurrence of early ovarian hyper-stimulation syndrome were all outcome variables in the primary research. Results: Data from 138 individuals in the CC-HCG group and 131 participants in the CC-Placebo group were subjected to final analysis. In comparison to the CC-Placebo group, the cycle cancellation rate in the CC-HCG group was considerably lower. The CC-HCG group exhibited a substantial increase in ovarian follicles reaching > 18 mm, endometrial thickness, and ovulation rate. The clinical pregnancy rate was higher in the CC-HCG group (7.2% vs. 2.3%; CC-HCG vs. CC-Placebo). Upon adjusting for BMI and age, the findings of our study revealed that individuals in the CC-HCG group who had serum prolactin levels below 20 (ng/mL), secondary infertility, infertility duration less than 4 years, baseline LH/FSH ratios below 1.5, and serum AMH levels more than 4 (ng/mL) had a higher likelihood of achieving pregnancy. In the CC-Placebo group, there was a greater prediction of clinical pregnancy for those with serum AMH (<4), primary infertility, serum prolactin ≤ 20 (ng/mL), baseline LH/FSH < 1.5, and infertility duration < 4 years. Conclusions: The use of a small dose of HCG along with CC appeared to be an effective treatment in reducing cycle cancelation, improving the clinical pregnancy rate and ovulation rate in CC-resistant PCOS patients. The trial was registered with Clinical Trials.gov, identifier NCT02436226

polycystic ovary syndromeclomiphene citrate resistancehuman chorionic gonadotropinovulation induction
مقالوصول مفتوح202244استشهاد· Semantic Scholar

A Multistage In Silico Study of Natural Potential Inhibitors Targeting SARS-CoV-2 Main Protease

International Journal of Molecular Sciences · مجلد 23 (15) · 8407-8407

Among a group of 310 natural antiviral natural metabolites, our team identified three compounds as the most potent natural inhibitors against the SARS-CoV-2 main protease (PDB ID: 5R84), Mpro. The identified compounds are sattazolin and caprolactin A and B. A validated multistage in silico study was conducted using several techniques. First, the molecular structures of the selected metabolites were compared with that of GWS, the co-crystallized ligand of Mpro, in a structural similarity study. The aim of this study was to determine the thirty most similar metabolites (10%) that may bind to the Mpro similar to GWS. Then, molecular docking against Mpro and pharmacophore studies led to the choice of five metabolites that exhibited good binding modes against the Mpro and good fit values against the generated pharmacophore model. Among them, three metabolites were chosen according to ADMET studies. The most promising Mpro inhibitor was determined by toxicity and DFT studies to be caprolactin A (292). Finally, molecular dynamics (MD) simulation studies were performed for caprolactin A to confirm the obtained results and understand the thermodynamic characteristics of the binding. It is hoped that the accomplished results could represent a positive step in the battle against COVID-19 through further in vitro and in vivo studies on the selected compounds.

main proteaseMpro inhibitorsnatural metabolitesstructural similarity